Topic · 1 report

Medicare Negotiation

RegulationWatch reporting on medicare negotiation matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.

  1. Medicare Negotiation

    Supreme Court declines drugmaker appeals against Medicare drug price negotiation program

    The US Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program created by the 2022 Inflation Reduction Act. The justices left in place Third Circuit rulings dismissing the manufacturers' claims without comment.